Neuro-ophthalmological Side Effect of Immune Checkpoint Inhibitors at a Tertiary Cancer Center

Immune checkpoint inhibitors (ICIs) are increasingly becoming the standard of care in cancer therapy. Despite their promising outcome from an oncological perspective, these treatments are associated with a variety of immune-related adverse events (irAEs). Neuro-ophthalmical irAEs such as myasthenia gravis (MG), myositis, Guillain-Barré syndrome (GBS), and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) associated with anti-PD-1, anti-PD-L1, and anti-CTLA-4 can be devastating. The aim of our study is to report the frequency, characteristics, treatment, and prognosis of side effects related to each class of ICI.